Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4535 Survival and toxicity outcomes of somatostatin analogues vs. other systemic therapies as first-line palliative treatment for patients with extrapulmonary G2 well-differentiated neuroendocrine tumours with a Ki-67 index between 10% and 20%

Introduction: In patients (pts) with an advanced well-differentiated (WD-NET) with a Ki-67>10% and ≤20% (“G2 high”), chemotherapy (ChT) or targeted therapies are the preferred first-line palliative options. Somatostatin analogues (SSAs) may offer an alternative, yet randomised evidence is lacking.

Conference:

Presenting Author:

Authors: Dawoodji A, Nuttall C, Eyong M, Farrell K, Barratt N,

Keywords: somatostatin analogue, SSA, non-SSA, Grade 2 well-differentiated neuroendocrine tumour, WD-NET,

#4466 Molecular characterisation of extrapulmonary mixed adeno-neuroendocrine neoplasms (MiNENs): The NIRVANA sub study

Introduction: Extrapulmonary (EP) mixed neuroendocrine/non-neuroendocrine neoplasms (MiNENs) are rare cancers with a dismal prognosis. The gene mutation profiles are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: MiNEN, NGS, ESCAT, chemotherapy,

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4392 Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,

#4046 A single institution experience of clinic-molecular characterisation and correlation with treatment outcomes in patients with advanced extrapulmonary high grade neuroendocrine carcinomas: The NIRVANA study

Introduction: The gene mutation profiles of extra-pulmonary (EP) neuroendocrine carcinomas (NECs) and mixed neuroendocrine / non-neuroendocrine carcinomas (MiNENs) are incompletely understood.

Conference:

Presenting Author: Spada F

Authors: Spada F, Pisa E, Ranghiero A, Frassoni S, Bagnardi V,

Keywords: NEC, MiNEN, NGS, KRAS, TP53, MSI, extra-pulmonary,